Arcutis Biotherapeutics, Inc. (ARQT) financial statements (2022 and earlier)

Company profile

Business Address 3027 TOWNSGATE ROAD
WESTLAKE VILLAGE, CA 91361
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 284,441
Cash and cash equivalents 65,082
Short-term investments 219,359
Prepaid expense 1,468
Other undisclosed current assets 6,917
Total current assets: 292,826
Noncurrent Assets
Operating lease, right-of-use asset 3,349
Property, plant and equipment 2,016
Other noncurrent assets 78
Total noncurrent assets: 5,443
TOTAL ASSETS: 298,269
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 22,602
Accounts payable 7,140
Accrued liabilities 15,462
Total current liabilities: 22,602
Noncurrent Liabilities
Long-term debt and lease obligation 4,964
Operating lease, liability 4,964
Liabilities, other than long-term debt 82
Other liabilities 82
Total noncurrent liabilities: 5,046
Total liabilities: 27,648
Stockholders' equity
Stockholders' equity attributable to parent 270,621
Common stock 4
Additional paid in capital 472,569
Accumulated other comprehensive loss (2)
Accumulated deficit (201,950)
Total stockholders' equity: 270,621
TOTAL LIABILITIES AND EQUITY: 298,269

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
Operating expenses (136,645)
Operating loss: (136,645)
Nonoperating income 967
Net loss available to common stockholders, diluted: (135,678)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
Net loss: (135,678)
Comprehensive loss: (135,678)
Other undisclosed comprehensive loss, net of tax, attributable to parent (1)
Comprehensive loss, net of tax, attributable to parent: (135,679)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: